Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021

On March 10, 2021 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported it will present preclinical data on three XmAb bispecific antibody programs and the IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held virtually April 10-15, 2021 (Press release, Xencor, MAR 10, 2021, View Source [SID1234576433]). Abstracts for these poster presentations are now available on AACR (Free AACR Whitepaper)’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details

Abstract 1743, "IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents"
Session: Immunomodulatory Agents and Interventions
Abstract: 1880, "PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors"
Session: Therapeutic Antibodies, Including Engineered Antibodies
Abstract: 1860, "Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells"
Session: Therapeutic Antibodies, Including Engineered Antibodies
Abstract: 1831, "Affinity tuned XmAb 2+1 GPC3 x CD3 bispecific antibodies demonstrate selective activity in liver cancer models"
Session: Therapeutic Antibodies, Including Engineered Antibodies
These posters will be available to registrants of the AACR (Free AACR Whitepaper) Annual Meeting at 8:30 a.m. EDT on Saturday, April 10. Posters will be archived under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com.